Search hospitals > Alberta > EDMONTON

Cross Cancer Institute

Claim this profile
EDMONTON, Alberta T6G 1Z2
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
739 reported clinical trials
37 medical researchers
Photo of Cross Cancer Institute in EDMONTONPhoto of Cross Cancer Institute in EDMONTONPhoto of Cross Cancer Institute in EDMONTON

Summary

Cross Cancer Institute is a medical facility located in EDMONTON, Alberta. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. Cross Cancer Institute is involved with conducting 739 clinical trials across 421 conditions. There are 37 research doctors associated with this hospital, such as Quincy Chu, Michael Chu, MD, Michael Kolinsky, and Samir I. Patel.

Area of expertise

1Skin Cancer
Global Leader
Cross Cancer Institute has run 96 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Cross Cancer Institute has run 93 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at Cross Cancer Institute

Multiple Myeloma
Breast Cancer
Lung Cancer
Lymphoma
Plasma Cell Neoplasm
Non-Small Cell Lung Cancer
Skin Cancer
Solid Tumors
Endometrial Cancer
Brain Tumor
Image of trial facility.

Elranatamab Access

for Multiple Myeloma

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Recruiting3 awards Phase 42 criteria
Image of trial facility.

Tec-DR and Tal-DR

for Multiple Myeloma

This trial is testing two new drug combinations to see if they work better than the current standard treatment for multiple myeloma. The new treatments aim to help the immune system find and destroy cancer cells more effectively.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Elranatamab

for Multiple Myeloma

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Recruiting2 awards Phase 36 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cross Cancer Institute?
Cross Cancer Institute is a medical facility located in EDMONTON, Alberta. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. Cross Cancer Institute is involved with conducting 739 clinical trials across 421 conditions. There are 37 research doctors associated with this hospital, such as Quincy Chu, Michael Chu, MD, Michael Kolinsky, and Samir I. Patel.
Where is Cross Cancer Institute located?
The Cross Cancer Institute is situated at 11560 University Avenue NW, Edmonton, Alberta, T6G 1Z2. It is accessible by car, with real-time driving directions available to account for traffic and road conditions. For those preferring public transportation, bus and light rail stations are located at 117 Street & University Avenue and 114 Street & 83 Avenue.
Who should I call to ask about financial aid or insurance network?
**Cross Cancer Institute Financial Assistance and Insurance Information:** - **Memorial Sloan Kettering Cancer Center:** For insurance inquiries, contact 646-497-9176, Monday through Friday. - **Northwell Health:** Offers a financial assistance program for those uninsured or underinsured. Eligibility is based on family size and income, determined through an application process. - **Roswell Park Comprehensive Cancer Center:** Provides financial assistance for New York State residents who are uninsured or struggling with out-of-pocket costs. Contact financial counselors at 716-845-4782. - **NYU Langone Health:** Financial assistance available for patients without insurance or with partial insurance coverage. Apply through the financial assistance application and consult a financial counselor at any listed location.
What insurance does Cross Cancer Institute accept?
For information on insurance plans accepted by the Cross Cancer Institute in Alberta, Canada, please contact the institute directly.
What awards or recognition has Cross Cancer Institute received?
The Cross Cancer Institute, located in Edmonton, Alberta, is renowned for its comprehensive healthcare services for cancer patients. It has been awarded $5 million by the Alberta Cancer Foundation to fund innovative cancer research projects, underscoring its dedication to improving cancer care and treatment.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security